Log in

Influence of steroid treatment's duration in patients with active Crohn's disease

  • Experimental Aspects of Gastrointestinal Inflammation New Approaches to Therapy of Gastrointestinal Inflammation General Inflammation Research Topics 3rd Meeting on Side Effects of Anti-Inflammatory Drugs and 13th European Workshop on Inflammation Verona, Italy
  • Short Communication Gastrointestinal Inflammation
  • Published:
Agents and Actions Aims and scope Submit manuscript

Abstract

Steroids are very useful drugs in the treatment of active Crohn's disease (CD), but clinical relapses after steroid withdrawal may be very high.

We investigated the efficacy of two steroid regimens of different duration in inducing remission and in maintaining it after drug suspension.

Patients with active CD were randomly assigned to scheme A, lasting 7 weeks (27 patients), or to scheme B, lasting 15 weeks (27 patients). Remission rates at the end of the treatment were 81% for scheme A and 85% for scheme B. Relapse rates at 6 months after stop** the treatment were 50% (11 patients) and 52% (12 patients), respectively.

Remission rates seem not to be influenced by the duration of the treatment, but patients recently treated with steroids showed a higher relapse rate if they received the short-duration treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. R. W. Summers, D. M. Switz, J. T. Sessions, J. M. Becktel, W. R. Best, F. Jr. Kern and J. W. Singleton,National Cooperative Crohn's Disease Study: Results of drug treatment. Gastroenterology77, 847–869 (1979).

    PubMed  Google Scholar 

  2. H. Malchow, K. Ewe, J. W. Brandes, H. Goebell, H. Ehms, H. Sommer and H. Jesdinsky,European Cooperative Crohn's Disease Study: Results of drug treatment. Gastroenterology86, 249–266 (1984).

    PubMed  Google Scholar 

  3. R. Modigliani, J. Y. Mary, J. F. Simon, A. Cortot, J. C. Soule, J. P. Gendre and E. Rene, GETAID,Clinical, biological, and endoscopic picture of attacks of Crohn's Disease. Evolution on prednisolone. Gastroenterology98, 811–818 (1990).

    PubMed  Google Scholar 

  4. R. M. Smith, J. Rodhes and D. L. Hughes,Effect of low dose steroids on clinical relapse in Crohn's disease. Gut19, 606–610 (1978).

    PubMed  Google Scholar 

  5. J. W. Singleton, D. H. Law, M. L. Kelley, H. S. Mekhjian and R. A. L. Sturdevant,National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology77, 870–883 (1979).

    PubMed  Google Scholar 

  6. W. Best, J. M. Becktel, J. W. Singleton and F. Kern,Development of a Crohn's disease activity index. Gastroenterology70, 439 (1976).

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brignola, C., De Simone, G., Iannone, P. et al. Influence of steroid treatment's duration in patients with active Crohn's disease. Agents and Actions 36 (Suppl 1), C90–C92 (1992). https://doi.org/10.1007/BF01991034

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01991034

Keywords

Navigation